Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Paclitaxel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 3/20 | 0.98 |
| ▸ | TUBB known ✓ | P07437 | 3/20 | 0.98 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 3/20 | 0.98 |
| ▸ | TUBA1B known ✓ | P68363 | 3/20 | 0.98 |
| ▸ | TUBA4A known ✓ | P68366 | 3/20 | 0.98 |
| ▸ | TUBB4B known ✓ | P68371 | 3/20 | 0.98 |
| ▸ | TUBB3 known ✓ | Q13509 | 3/20 | 0.98 |
| ▸ | TUBB2A known ✓ | Q13885 | 3/20 | 0.98 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 3/20 | 0.98 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 3/20 | 0.98 |
| ▸ | TUBA1A known ✓ | Q71U36 | 3/20 | 0.98 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 3/20 | 0.98 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 3/20 | 0.98 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 3/20 | 0.98 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 3/20 | 0.98 |
| ▸ | NPC1 | O15118 | 8/20 | 0.98 |
| ▸ | RAB9A | P51151 | 7/20 | 0.98 |
| ▸ | USP2 | O75604 | 2/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paclitaxel SCHEMBL13241436 | 0.99 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL125950 | 0.99 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL19996646 | 0.99 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760447 | 0.99 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL759366 | 0.99 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL23760443 | 0.99 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL12929005 | 0.99 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL15590870 | 0.99 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL22149786 | 0.99 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C | |
| Paclitaxel SCHEMBL13622863 | 0.99 | NPC1 (1.00) | NPC1RAB9ATUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105944-A1 | Taxane metabolites | COMEZOGLU S N | 2007-05-10 | — | — | US | disclosed |
| EP-1425407-A4 | ENZYMATIC RESOLUTION OF T-BUTYL TAXANE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7063977-B2 | Enzymatic resolution of t-butyl taxane derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
| EP-1556030-A2 | TAXANE METABOLITES | Bristol-Myers Squibb Company (US) | 2005-07-27 | — | — | EP | disclosed |
| US-6916942-B2 | Process for the preparation of C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040225009-A1 | Process for the preparation of C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| EP-1251846-B1 | C-4 CARBONATE TAXANES | BRISTOL MYERS SQUIBB CO (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6750246-B1 | NOVEL ORALLY ACTIVE PACLITAXEL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-15 | — | — | US | disclosed |
| EP-1425407-A2 | ENZYMATIC RESOLUTION OF T-BUTYL TAXANE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2004037211-A2 | TAXANE METABOLITES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20030069415-A1 | Enzymatic resolution of t-butyl taxane derivatives | BRISTON-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| EP-1251846-A4 | C-4 CARBONATE TAXANES | BRISTOL MYERS SQUIBB CO (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2003016543-A2 | ENZYMATIC RESOLUTION OF T-BUTYL TAXANE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1251846-A1 | C-4 CARBONATE TAXANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001056565-A1 | C-4 CARBONATE TAXANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| US-5840929-A | ANTITUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105944-A1 | Taxane metabolites | TERT, XPO5, PARP3 | TUBB4A 63/4885TUBB 46/4885TUBA3C 74/4885 |
| US-20030069415-A1 | Enzymatic resolution of t-butyl taxane derivatives | THOP1, BCHE, CES1 | TUBB4A 1061/4885TUBB 552/4885TUBA3C 1094/4885 |
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | CA4, CA14, CA13 | TUBB4A 20/4885TUBB 309/4885TUBA3C 116/4885 |
| US-20040225009-A1 | Process for the preparation of C-4 carbonate taxanes | CA4, CA14, CDK4 | TUBB4A 104/4885TUBB 1036/4885TUBA3C 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.